Clinical Practice

Use the tool below to view all available Global Neurology Academy Series

Recognizing the Signs of TK2 Deficiency
Recognizing the Signs of TK2 Deficiency
NeuroFrontiers
Recognizing the Signs of TK2 Deficiency
Kaitlin Batley, MD
- Kaitlin Batley, MD
Reimagining Alzheimer's Care: The Advent of Subcutaneous Administration of Anti-Amyloid Therapy
Reimagining Alzheimer's Care: The Advent of Subcutaneous Administration of Anti-Amyloid Therapy
CME/CE
Reimagining Alzheimer's Care: The Advent of Subcutaneous Administration of Anti-Amyloid Therapy
R. Scott Turner, MD, PhD
0.25 credits
- R. Scott Turner, MD, PhD
0.25 credits
A Closer Look at the Biology Behind MS Progression
A Closer Look at the Biology Behind MS Progression
NeuroFrontiers
A Closer Look at the Biology Behind MS Progression
Ethan Meltzer, MD
- Ethan Meltzer, MD
Exploring Genetic Links Between EBV Clearance and MS Risk
Exploring Genetic Links Between EBV Clearance and MS Risk
NeuroFrontiers
Exploring Genetic Links Between EBV Clearance and MS Risk
David Hafler, MD, FANA, MSc
- David Hafler, MD, FANA, MSc
The Role of B-Cell Depletion in MS Care
The Role of B-Cell Depletion in MS Care
NeuroFrontiers
The Role of B-Cell Depletion in MS Care
David Hafler, MD, FANA, MSc
- David Hafler, MD, FANA, MSc
Precision Medicine for Myasthenia Gravis
Precision Medicine for Myasthenia Gravis
NeuroFrontiers
Precision Medicine for Myasthenia Gravis
Shruti Raja, MD, MHS
- Shruti Raja, MD, MHS
The New Era of Targeted Therapy for Myasthenia Gravis
The New Era of Targeted Therapy for Myasthenia Gravis
NeuroFrontiers
The New Era of Targeted Therapy for Myasthenia Gravis
Shruti Raja, MD, MHS
- Shruti Raja, MD, MHS
Outcome Measures Capture Progression in Late-Onset TK2d
Outcome Measures Capture Progression in Late-Onset TK2d
NeuroFrontiers
Outcome Measures Capture Progression in Late-Onset TK2d
More Than a Myopathy: The Lived Experience of TK2d
More Than a Myopathy: The Lived Experience of TK2d
NeuroFrontiers
More Than a Myopathy: The Lived Experience of TK2d
ADHD After 25 Years: What Have We Learned?
ADHD After 25 Years: What Have We Learned?
NeuroFrontiers
ADHD After 25 Years: What Have We Learned?
James Swanson, PhD
- James Swanson, PhD
ADHD Medication Dose-Effect Patterns Vary by Age and Drug Class
ADHD Medication Dose-Effect Patterns Vary by Age and Drug Class
NeuroFrontiers
ADHD Medication Dose-Effect Patterns Vary by Age and Drug Class
Diagnosing Adult ADHD in the Social Media Era
Diagnosing Adult ADHD in the Social Media Era
NeuroFrontiers
Diagnosing Adult ADHD in the Social Media Era
Jill RachBeisel, MD
- Jill RachBeisel, MD
Untangling ADHD from Depression, Anxiety, and Substance Use Disorder
Untangling ADHD from Depression, Anxiety, and Substance Use Disorder
NeuroFrontiers
Untangling ADHD from Depression, Anxiety, and Substance Use Disorder
Jill RachBeisel, MD
- Jill RachBeisel, MD
Navigating the Limitations of Current BD Therapies
Navigating the Limitations of Current BD Therapies
MinuteCE®
Navigating the Limitations of Current BD Therapies
Jose M. Rubio, MD, PhD; Sunny X. Tang, MD
0.50 program credits
- Jose M. Rubio, MD, PhD
- Sunny X. Tang, MD
0.50 program credits
Recurrence as the Rule: BD Symptoms Persist and Cycle
Recurrence as the Rule: BD Symptoms Persist and Cycle
MinuteCE®
Recurrence as the Rule: BD Symptoms Persist and Cycle
Jose M. Rubio, MD, PhD; Sunny X. Tang, MD
0.50 program credits
- Jose M. Rubio, MD, PhD
- Sunny X. Tang, MD
0.50 program credits
MinuteCE®
Exploring the Potential Role of Emerging Muscarinic Therapies in the Treatment of Bipolar Disorder
Jose M. Rubio, MD, PhD; Sunny X. Tang, MD
0.50 credits 5 episodes
- Jose M. Rubio, MD, PhD
- Sunny X. Tang, MD
0.50 credits 5 episodes

Clinical Practice

Popular

NEED HELP?

Contact us

NEED HELP?

Contact us

Clinical Practice

Popular

Title